A cellular autoreactive immune response involving a repertoire of CD4+ Th cells, particularly Th1 and Th17, is considered characteristic of MS onset and progression, whereas regulatory cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)-β and Th2 cells, releasing IL-4, IL-5, IL-13 and IL-25, are related to anti-inflammatory effects and recovery [41]. This evidence concerns the gene CD4 and myeloid sarcoma.